Nancy J. Brown

Q: What Schools Are Affiliated With Nancy J. Brown

Nancy J. Brown is affiliated with the following schools: University of California, Berkeley, Université de Montréal, Yale University, University of California, Irvine, Wayne State University, Vanderbilt University, Stanford University, University of North Carolina at Chapel Hill, Columbia University

Nancy J. Brown's AcademicInfluence.com Rankings

Nancy J. Brown

Engineering

#6232

World Rank

#7547

Historical Rank

Bioengineering

#65

World Rank

#67

Historical Rank

Biomedical Engineering

#536

World Rank

#546

Historical Rank

Applied Physics

#1965

World Rank

#2000

Historical Rank

engineering Degrees

Nancy J. Brown

Biology

#11539

World Rank

#14941

Historical Rank

Molecular Biology

#1781

World Rank

#1810

Historical Rank

Biochemistry

#1913

World Rank

#2054

Historical Rank

biology Degrees

Download Badge

Engineering
Biology

Nancy J. Brown's Degrees

Masters Biochemistry Stanford University

Why Is Nancy J. Brown Influential?

(Suggest an Edit or Addition)

(See a Problem?)

Nancy J. Brown's Published Works

Number of citations in a given year to any of this author's works

Total number of citations to an author for the works they published in a given year. This highlights publication of the most important work(s) by the author

Published Works

Angiotensin-converting enzyme inhibitors. (1998) (669)
Established and emerging plasma biomarkers in the prediction of first atherothrombotic events. (2004) (458)
Effect of bradykinin-receptor blockade on the response to angiotensin-converting-enzyme inhibitor in normotensive and hypertensive subjects. (1998) (439)
The kallikrein-kinin system: current and future pharmacological targets. (2005) (433)
Prevention of obesity and insulin resistance in mice lacking plasminogen activator inhibitor 1. (2004) (403)
Effect of activation and inhibition of the renin-angiotensin system on plasma PAI-1. (1998) (299)
Contribution of aldosterone to cardiovascular and renal inflammation and fibrosis (2013) (275)
G protein-coupled receptor kinase 4 gene variants in human essential hypertension (2002) (271)
Aldosterone modulates plasminogen activator inhibitor-1 and glomerulosclerosis in vivo. (2000) (258)
Aldosterone and end-organ damage. (2005) (257)
Clinical Guidelines for the Use of Buprenorphine in the Treatment of Opioid Addiction. Treatment Improvement Protocol (TIP) Series 40. (2004) (244)
Aldosterone and vascular inflammation. (2008) (220)
Synergistic effect of adrenal steroids and angiotensin II on plasminogen activator inhibitor-1 production. (2000) (202)
Dipeptidyl Peptidase-IV Inhibitor Use Associated With Increased Risk of ACE Inhibitor-Associated Angioedema (2009) (198)
Uric acid and the state of the intrarenal renin-angiotensin system in humans. (2004) (197)
High-Dose Perioperative Atorvastatin and Acute Kidney Injury Following Cardiac Surgery: A Randomized Clinical Trial. (2016) (196)
Angiotensin converting enzyme gene polymorphism: potential silencer motif and impact on progression in IgA nephropathy. (1996) (193)
Functional Variant of CYP4A11 20-Hydroxyeicosatetraenoic Acid Synthase Is Associated With Essential Hypertension (2005) (187)
Regression of existing glomerulosclerosis by inhibition of aldosterone. (2005) (179)
Bradykinin Stimulates Tissue Plasminogen Activator Release From Human Forearm Vasculature Through B2 Receptor–Dependent, NO Synthase–Independent, and Cyclooxygenase-Independent Pathway (2000) (178)
Bradykinin stimulates tissue plasminogen activator release in human vasculature. (1999) (167)
Plasminogen Activator Inhibitor-1 Deficiency Prevents Hypertension and Vascular Fibrosis in Response to Long-term Nitric Oxide Synthase Inhibition (2001) (166)
Selective Stimulation of Tissue-Type Plasminogen Activator (t-PA) In Vivo by Infusion of Bradykinin (1997) (161)
Combined Angiotensin Receptor Antagonism and Neprilysin Inhibition (2016) (156)
Angiotensin-converting enzyme insertion/deletion polymorphism modulates the human in vivo metabolism of bradykinin. (2000) (155)
Interactive Hemodynamic Effects of Dipeptidyl Peptidase-IV Inhibition and Angiotensin-Converting Enzyme Inhibition in Humans (2010) (153)
Mitochondrial dysfunction and oxidative stress in patients with chronic kidney disease (2016) (151)
Possible Medication Errors in Home Healthcare Patients (2001) (148)
Angiotensin-converting enzyme inhibitor-associated angioedema. (2006) (142)
The renin-angiotensin-aldosterone system and glucose homeostasis. (2011) (141)
An application of conditional logistic regression and multifactor dimensionality reduction for detecting gene-gene Interactions on risk of myocardial infarction: The importance of model validation (2004) (141)
Eplerenone: Cardiovascular Protection (2003) (138)
Angiotensin II Induces Interleukin-6 in Humans Through a Mineralocorticoid Receptor–Dependent Mechanism (2006) (137)
Dipeptidyl Peptidase IV in Angiotensin-Converting Enzyme Inhibitor–Associated Angioedema (2006) (136)
Comparative effect of angiotensin-converting enzyme inhibition and angiotensin II type 1 receptor antagonism on plasma fibrinolytic balance in humans. (1999) (134)
Aldosterone and inflammation (2010) (131)
Prothrombotic effects of angiotensin. (2000) (130)
Obesity and oxidative stress predict AKI after cardiac surgery. (2012) (126)
Aldosterone and end-organ damage (2005) (125)
Frequency of functionally important beta-2 adrenoceptor polymorphisms varies markedly among African-American, Caucasian and Chinese individuals. (1999) (125)
Prevalence of primary hyperaldosteronism in mild to moderate hypertension without hypokalaemia (2006) (120)
ACE insertion/deletion genotype affects bradykinin metabolism. (1998) (118)
A variant in XPNPEP2 is associated with angioedema induced by angiotensin I-converting enzyme inhibitors. (2005) (114)
Variation in the 4q25 Chromosomal Locus Predicts Atrial Fibrillation After Coronary Artery Bypass Graft Surgery (2009) (110)
Proteomic patterns and prediction of glomerulosclerosis and its mechanisms. (2005) (110)
Improving Medication Use in Newly Admitted Home Healthcare Patients: A Randomized Controlled Trial (2002) (109)
Single nucleotide polymorphisms in the CYP2J2 and CYP2C8 genes and the risk of hypertension (2005) (109)
Aldosterone antagonism or synthase inhibition reduces end-organ damage induced by treatment with angiotensin and high salt. (2009) (107)
Increased Sensitivity to Angiotensin II Is Present Postpartum in Women With a History of Hypertensive Pregnancy (2010) (106)
Recurrent Angiotensin‐Converting Enzyme Inhibitor‐Associated Angioedema (1998) (106)
Dipeptidyl Peptidase IV Activity in Patients With ACE-Inhibitor-Associated Angioedema (2002) (105)
Thyroid function and blood pressure homeostasis in euthyroid subjects. (2004) (103)
Regulation of local tissue-type plasminogen activator release by endothelium-dependent and endothelium-independent agonists in human vasculature. (1998) (103)
Angiotensin-Converting Enzyme Inhibition Increases Human Vascular Tissue-Type Plasminogen Activator Release Through Endogenous Bradykinin (2003) (102)
Pharmacological Inhibition and Genetic Deficiency of Plasminogen Activator Inhibitor-1 Attenuates Angiotensin II/Salt-Induced Aortic Remodeling (2004) (101)
Risk for Hospitalized Heart Failure Among New Users of Saxagliptin, Sitagliptin, and Other Antihyperglycemic Drugs (2016) (95)
Plasminogen activator inhibitor-1 deficiency protects against aldosterone-induced glomerular injury. (2006) (92)
ACE Inhibition Versus Angiotensin Type 1 Receptor Antagonism: Differential Effects on PAI-1 Over Time (2002) (88)
Spironolactone abolishes the relationship between aldosterone and plasminogen activator inhibitor-1 in humans. (2002) (87)
Increased sensitivity to bradykinin among African Americans. (1996) (87)
Metabolism of bradykinin In vivo in humans: identification of BK1-5 as a stable plasma peptide metabolite. (2000) (85)
Serum metabolism of bradykinin and des-Arg9-bradykinin in patients with angiotensin-converting enzyme inhibitor-associated angioedema. (1999) (84)
Low-salt diet increases insulin resistance in healthy subjects. (2011) (83)
Milrinone Use Is Associated With Postoperative Atrial Fibrillation After Cardiac Surgery (2008) (83)
Human β2‐adrenergic receptor polymorphisms: No association with essential hypertension in black or white Americans (2000) (81)
Ala92 Type 2 Deiodinase Allele Increases Risk for the Development of Hypertension (2007) (80)
Differential Effects of Nebivolol and Metoprolol on Insulin Sensitivity and Plasminogen Activator Inhibitor in the Metabolic Syndrome (2012) (76)
Sex-dependent and race-dependent association of XPNPEP2 C-2399A polymorphism with angiotensin-converting enzyme inhibitor-associated angioedema (2010) (74)
The T8590C Polymorphism of CYP4A11 and 20-Hydroxyeicosatetraenoic Acid in Essential Hypertension (2008) (73)
Early postoperative statin therapy is associated with a lower incidence of acute kidney injury after cardiac surgery. (2010) (69)
Genetic variants associated with angiotensin-converting enzyme inhibitor-associated angioedema (2013) (68)
The Vasculature in Prediabetes. (2018) (68)
Combined angiotensin-converting enzyme inhibition and receptor blockade associate with increased risk of cardiovascular death in hemodialysis patients. (2011) (65)
Substance P Increases Sympathetic Activity During Combined Angiotensin-Converting Enzyme and Dipeptidyl Peptidase-4 Inhibition (2014) (64)
Plasminogen Activator Inhibitor-1 as a Predictor of Postoperative Atrial Fibrillation After Cardiopulmonary Bypass (2007) (63)
Relationship Between Carbamoyl-Phosphate Synthetase Genotype and Systemic Vascular Function (2004) (62)
Treatment with Sildenafil Improves Insulin Sensitivity in Prediabetes: A Randomized, Controlled Trial. (2015) (62)
Comparative Effects of Estrogen and Angiotensin-Converting Enzyme Inhibition on Plasminogen Activator Inhibitor-1 in Healthy Postmenopausal Women (2002) (62)
Aldosterone deficiency and mineralocorticoid receptor antagonism prevent angiotensin II-induced cardiac, renal, and vascular injury (2012) (60)
Altered frequency of a promoter polymorphism of the kinin B2 receptor gene in hypertensive African-Americans. (2000) (58)
Effect of bradykinin receptor antagonism on ACE inhibitor‐associated angioedema (2017) (58)
Alpha1A-adrenergic receptor polymorphism: association with ethnicity but not essential hypertension. (1999) (57)
Genetic Variation in Soluble Epoxide Hydrolase (EPHX2) Is Associated With Forearm Vasodilator Responses in Humans (2011) (56)
Oxidative Stress Biomarkers and Incidence of Postoperative Atrial Fibrillation in the Omega-3 Fatty Acids for Prevention of Postoperative Atrial Fibrillation (OPERA) Trial (2015) (55)
Simultaneous determination of uric acid metabolites allantoin, 6-aminouracil, and triuret in human urine using liquid chromatography-mass spectrometry. (2009) (54)
Smoking Impairs Bradykinin-Stimulated t-PA Release (2002) (52)
Comparative effects of angiotensin-converting enzyme inhibition and angiotensin-receptor blockade on inflammation during hemodialysis. (2012) (52)
Recurrent angiotensin-converting enzyme inhibitor-associated angioedema (1997) (51)
Gender affects renal vasoconstrictor response to Ang I and Ang II. (1998) (51)
Association of a CYP4A11 variant and blood pressure in black men. (2008) (51)
Angiotensin-converting enzyme inhibition or mineralocorticoid receptor blockade do not affect prevalence of atrial fibrillation in patients undergoing cardiac surgery* (2012) (50)
POLYMORPHISMS IN THE SERUM- AND GLUCOCORTICOID-INDUCIBLE KINASE 1 GENE ARE ASSOCIATED WITH BLOOD PRESSURE AND RENIN RESPONSE TO DIETARY SALT INTAKE (2012) (50)
The Fok1 vitamin D receptor gene polymorphism is associated with plasma renin activity in Caucasians (2011) (49)
Environmentally determined genetic expression: clinical correlates with molecular variants of carbamyl phosphate synthetase I. (2004) (48)
Review: Therapeutic potential of plasminogen activator inhibitor-1 inhibitors (2010) (48)
Cardiovascular Disease Risk Factors in Ghana during the Rural-to-Urban Transition: A Cross-Sectional Study (2016) (47)
Inhibition of aminopeptidase P potentiates wheal response to bradykinin in angiotensin-converting enzyme inhibitor-treated humans. (2000) (45)
Quantification of BK1-5, the stable bradykinin plasma metabolite in humans, by a highly accurate liquid-chromatographic tandem mass spectrometric assay. (2001) (45)
Characterization of the CYP4A11 gene, a second CYP4A gene in humans. (2003) (45)
CYP4A11 T8590C polymorphism, salt-sensitive hypertension, and renal blood flow (2011) (44)
Characterization of Genome-Wide Association-Identified Variants for Atrial Fibrillation in African Americans (2012) (44)
Effects of acute angiotensin II type 1 receptor antagonism and angiotensin converting enzyme inhibition on plasma fibrinolytic parameters in patients with heart failure. (2000) (44)
The renin-angiotensin-aldosterone system and fibrinolysis in progressive renal disease. (2002) (44)
Polymorphisms in the transcription factor NRF2 and forearm vasodilator responses in humans (2012) (43)
Dipeptidyl peptidase IV deficiency increases susceptibility to angiotensin-converting enzyme inhibitor-induced peritracheal edema. (2007) (43)
Phosphodiesterase 5 Inhibition Improves β-Cell Function in Metabolic Syndrome (2009) (43)
Interactive Effect of Ethnicity and ACE Insertion/Deletion Polymorphism on Vascular Reactivity (2001) (42)
β-2 Adrenergic Receptor Diplotype Defines a Subset of Salt-Sensitive Hypertension (2006) (42)
Angiotensin-(1-7) Does Not Affect Vasodilator or TPA Responses to Bradykinin in Human Forearm (2001) (42)
PAI-1 in human hypertension: relation to hypertensive groups. (2002) (41)
Aldosterone and PAI-1: implications for renal injury. (2002) (41)
Bradykinin Type 2 Receptor BE1 Genotype Influences Bradykinin-Dependent Vasodilation During Angiotensin-Converting Enzyme Inhibition (2008) (40)
Association of angiotensin‐converting enzyme inhibitor‐associated angioedema with transplant and immunosuppressant use (2010) (40)
Genetic variation in CYP4A11 and blood pressure response to mineralocorticoid receptor antagonism or ENaC inhibition: an exploratory pilot study in African Americans. (2014) (39)
Skeletal Muscle Mitochondrial Dysfunction Is Present in Patients with CKD before Initiation of Maintenance Hemodialysis. (2020) (39)
Interactive Effect of PAI-1 4G/5G Genotype and Salt Intake on PAI-1 Antigen (2001) (38)
Ethnicity Affects Vasodilation, but Not Endothelial Tissue Plasminogen Activator Release, in Response to Bradykinin (2002) (38)
Bradykinin and Its Metabolite Bradykinin 1-5 Inhibit Thrombin-Induced Platelet Aggregation in Humans (2006) (38)
Lysine-specific demethylase 1: an epigenetic regulator of salt-sensitive hypertension. (2012) (38)
Effect of combined AT1 receptor and aldosterone receptor antagonism on plasminogen activator inhibitor-1. (2003) (38)
Acquisition, Analysis, and Sharing of Data in 2015 and Beyond: A Survey of the Landscape (2015) (37)
Angiotensin converting enzyme inhibitor‐associated angioedema: higher risk in blacks than whites (1996) (37)
The Preparation and Characterization of Novel Peptide Antagonists to Thrombin and Factor VIIa and Activation of Protease-Activated Receptor 1 (2004) (37)
Intraoperative Oxidative Damage and Delirium after Cardiac Surgery (2019) (36)
An LC-MS assay for the screening of cardiovascular medications in human samples. (2013) (35)
Cardiovascular effects of antidiabetic agents: focus on blood pressure effects of incretin-based therapies. (2012) (35)
Potential roles of plasminogen activator system in coronary vascular remodeling induced by long-term nitric oxide synthase inhibition. (2002) (35)
Differential effects of angiotensin converting enzyme inhibitors on the vasodepressor and prostacyclin responses to bradykinin. (1996) (34)
Angiotensin-converting Enzyme Inhibitor and Other Drug-associated Angioedema. (2017) (34)
Arg287Gln variant of EPHX2 and epoxyeicosatrienoic acids are associated with insulin sensitivity in humans. (2014) (34)
Pharmacogenomics of off‐target adverse drug reactions (2017) (34)
A prevalent caveolin-1 gene variant is associated with the metabolic syndrome in Caucasians and Hispanics. (2015) (33)
A model for improving medication use in home health care patients. (1998) (33)
Bradykinin forming capacity of oversulfated chondroitin sulfate contaminated heparin in vitro. (2010) (31)
Losartan blocks aldosterone and renal vascular responses to angiotensin II in humans. (1996) (31)
Dipeptidyl‐Peptidase 4 Inhibition and the Vascular Effects of Glucagon‐like Peptide‐1 and Brain Natriuretic Peptide in the Human Forearm (2014) (31)
Prospective study of the incidence and predictors of thrombus in children undergoing palliative surgery for single ventricle physiology (2011) (30)
The Bradykinin Type 2 Receptor BE1 Polymorphism and Ethnicity Influence Systolic Blood Pressure and Vascular Resistance (2008) (30)
Fenofibrate lowers blood pressure in salt-sensitive but not salt-resistant hypertension (2013) (30)
Differing effects of mineralocorticoid receptor-dependent and -independent potassium-sparing diuretics on fibrinolytic balance. (2005) (29)
Contribution of bradykinin to the cardioprotective effects of ACE inhibitors (2003) (29)
The Renin-Angiotensin and fibrinolytic systems co-conspirators in the pathogenesis of ischemic cardiovascular disease. (1996) (29)
Plasma Phospholipid Omega‐3 Fatty Acids and Incidence of Postoperative Atrial Fibrillation in the OPERA Trial (2013) (28)
Beta-2 adrenergic receptor diplotype defines a subset of salt-sensitive hypertension. (2006) (28)
A pharmacodynamic interaction between caffeine and phenylpropanolamine (1991) (28)
Angiotensin-Converting Enzyme Inhibition Alters the Fibrinolytic Response to Cardiopulmonary Bypass (2003) (27)
Renin gene polymorphism: its relationship to hypertension, renin levels and vascular responses (2011) (26)
Adipose Tissue in Persons With HIV Is Enriched for CD4+ T Effector Memory and T Effector Memory RA+ Cells, Which Show Higher CD69 Expression and CD57, CX3CR1, GPR56 Co-expression With Increasing Glucose Intolerance (2019) (26)
Epoxyeicosatrienoic acids and glucose homeostasis in mice and men. (2016) (25)
Heart failure event definitions in drug trials in patients with type 2 diabetes. (2016) (25)
Acute tissue-type plasminogen activator release in human microvascular endothelial cells: The roles of Gαq, PLC-β, IP3 and 5,6-epoxyeicosatrienoic acid (2007) (25)
Male–female differences in the genetic regulation of t-PA and PAI-1 levels in a Ghanaian population (2008) (24)
Risk Factor Interactions and Genetic Effects Associated with Post-Operative Atrial Fibrillation (2005) (23)
Angiotensin-Converting Enzyme Inhibition Increases Basal Vascular Tissue Plasminogen Activator Release in Women But Not in Men (2005) (23)
NO Synthase Inhibition Increases Aldosterone in Humans (2004) (23)
Caffeine potentiates the renin response to diazoxide in man. Evidence for a regulatory role of endogenous adenosine. (1989) (23)
Dietary sodium restriction decreases insulin secretion without affecting insulin sensitivity in humans. (2014) (23)
Urinary free cortisol: an intermediate phenotype and a potential genetic marker for a salt-resistant subset of essential hypertension. (2007) (22)
Systolic Blood Pressure and Biochemical Assessment of Adherence: A Cross-Sectional Analysis in the Emergency Department (2017) (21)
Caffeine attenuates the renal vascular response to angiotensin II infusion. (1993) (21)
Acute angiotensin II increases plasma F2-isoprostanes in salt-replete human hypertensives. (2003) (21)
Contribution of Endogenous Bradykinin to Fibrinolysis, Inflammation, and Blood Product Transfusion Following Cardiac Surgery: A Randomized Clinical Trial (2013) (21)
Plasminogen Activator Inhibitor‐1 and Diagnosis of the Metabolic Syndrome in a West African Population (2016) (20)
Endogenous bradykinin contributes to increased plasminogen activator inhibitor 1 antigen following hemodialysis. (2009) (20)
DPP (Dipeptidyl Peptidase)-4 Inhibition Potentiates the Vasoconstrictor Response to NPY (Neuropeptide Y) in Humans During Renin-Angiotensin-Aldosterone System Inhibition (2018) (19)
Angiotensin converting enzyme inhibition increases ADMA concentration in patients on maintenance hemodialysis – a randomized cross-over study (2015) (19)
Early urine electrolyte patterns in patients with acute heart failure (2018) (19)
Tissue‐ and agonist‐specific regulation of human and murine plasminogen activator inhibitor‐1 promoters in transgenic mice (2003) (19)
Acute tissue-type plasminogen activator release in human microvascular endothelial cells: the roles of Galphaq, PLC-beta, IP3 and 5,6-epoxyeicosatrienoic acid. (2007) (18)
Hypertension Is Associated With Preamyloid Oligomers in Human Atrium: A Missing Link in Atrial Pathophysiology? (2014) (18)
Fish Oil and Perioperative Bleeding: Insights From the OPERA Randomized Trial (2018) (18)
Angiotensin II type I Receptor polymorphism in African Americans lower frequency of the C1166 variant (1997) (18)
Sitagliptin decreases visceral fat and blood glucoses in women with polycystic ovarian syndrome. (2019) (18)
Clinician Innovator: A Novel Career Path in Academic Medicine (2015) (18)
Endogenous aldosterone contributes to acute angiotensin II-stimulated plasminogen activator inhibitor-1 and preproendothelin-1 expression in heart but not aorta. (2009) (16)
Variation in the 4 q 25 Chromosomal Locus Predicts Atrial Fibrillation After Coronary Artery Bypass Graft Surgery (2009) (16)
Hypertension and Type 2 Diabetes Are Associated With Decreased Inhibition of Dipeptidyl Peptidase-4 by Sitagliptin (2017) (16)
B-Type Natriuretic Peptide, Aldosterone, and Fluid Management in ARDS. (2016) (16)
Loss of Sodium Modulation of Plasma Kinins in Human Hypertension (2004) (16)
Functional BSND variants in essential hypertension. (2007) (16)
Comparative Effects of Angiotensin Receptor BlockadeandACE Inhibition on the Fibrinolytic and Inflammatory Responses to Cardiopulmonary Bypass (2012) (15)
A pilot study indicating that bradykinin B2 receptor antagonism attenuates protamine‐related hypotension after cardiopulmonary bypass (2005) (15)
A Variant in XPNPEP 2 Is Associated with Angioedema Induced by Angiotensin I – Converting Enzyme Inhibitors (2005) (15)
Aprepitant for the Treatment of Pruritus in Sézary Syndrome: A Randomized Crossover Clinical Trial (2018) (15)
Modulation of angiotensin II and norepinephrine-induced plasminogen activator inhibitor-1 expression by AT1a receptor deficiency. (2007) (14)
Endogenous bradykinin and B1-B5 during angiotensin-converting enzyme inhibitor-associated angioedema. (2018) (13)
17&bgr;-Estradiol Increases Basal but Not Bradykinin-Stimulated Release of Active t-PA in Young Postmenopausal Women (2008) (13)
Phenotype-Driven Plasma Biobanking Strategies and Methods (2015) (13)
A population-based study in Ghana to investigate inter-individual variation in plasma t-PA and PAI-1. (2007) (13)
Endogenous Nitric Oxide Contributes to Bradykinin-Stimulated Glucose Uptake but Attenuates Vascular Tissue-Type Plasminogen Activator Release (2010) (13)
Association of gain-of-function EPHX2 polymorphism Lys55Arg with acute kidney injury following cardiac surgery (2017) (13)
Quantitative Imaging of Preamyloid Oligomers, a Novel Structural Abnormality, in Human Atrial Samples (2014) (13)
Angiotensin‐converting enzyme inhibition and smoking potentiate the kinin response to cardiopulmonary bypass (2004) (12)
Characteristics and treatment of African-American and European-American patients with resistant hypertension identified using the electronic health record in an academic health centre: a case−control study (2018) (12)
Role of Angiotensin II in Coagulation and Fibrinolysis (2004) (12)
Blood pressure reduction and tissue-type plasminogen activator release. (2006) (11)
Dipeptidyl Peptidase 4 Inhibition Increases Postprandial Norepinephrine via Substance P (NK1 Receptor) During RAAS Inhibition (2019) (11)
The relationship between peroxisome proliferator-activated receptor-gamma and renin: a human genetics study. (2010) (11)
This is not Dr. Conn's aldosterone anymore. (2011) (10)
Exome Sequencing Reveals Common and Rare Variants in F5 Associated With ACE Inhibitor and Angiotensin Receptor Blocker–Induced Angioedema (2020) (10)
CYP4A11 variant is associated with high density lipoprotein cholesterol in women (2011) (10)
Association of a glucagon‐like peptide‐1 receptor gene variant with glucose response to a mixed meal (2020) (9)
Bradykinin B2 Receptor Does Not Contribute to Blood Pressure Lowering during AT1 Receptor Blockade (2007) (9)
Pollen count and presentation of angiotensin-converting enzyme inhibitor-associated angioedema. (2013) (9)
Endogenous bradykinin and the renin and pressor responses to furosemide in humans. (2000) (9)
Octreotide: a long-acting somatostatin analog. (1990) (9)
Genetics of Plasminogen Activator Inhibitor-1 (PAI-1) in a Ghanaian Population (2015) (9)
Endogenous NO Regulates Plasminogen Activator Inhibitor-1 During Angiotensin-Converting Enzyme Inhibition (2006) (9)
Dipeptidyl Peptidase‐4 Inhibition Potentiates Stimulated Growth Hormone Secretion and Vasodilation in Women (2018) (8)
Abstracts from the 10th C1-inhibitor deficiency workshop (2017) (8)
Quantification of neuropeptide Y and four of its metabolites in human plasma by micro-UHPLC-MS/MS. (2019) (7)
Sitagliptin decreases visceral fat and blood glucoses in women with polycystic ovarian syndrome (2019) (7)
Angiotensin receptor blocker vs ACE inhibitor effects on HDL functionality in patients on maintenance hemodialysis. (2018) (7)
Two Pools of Epoxyeicosatrienoic Acids in Humans: Alterations in Salt-Sensitive Normotensive Subjects (2018) (6)
Glucagon-Like Peptide-1 Receptor Regulates Thromboxane-Induced Human Platelet Activation (2022) (6)
Higher urinary cortisol levels associate with increased cardiovascular risk (2019) (6)
Increased blood flow induces oxidative stress through an endothelium- and nitric oxide-independent mechanism. (2010) (6)
Active BNP Measured by Mass Spectrometry and Response to Sacubitril/Valsartan: BNP by MS and Response to Sacubitril/Valsartan. (2021) (6)
Lanadelumab And Cardiovascular Risk: Findings From The Phase 3 HELP Study: 136 (2019) (6)
Fish Oil Supplementation Does Not Affect Cognitive Outcomes in Cardiac Surgery Patients in the Omega-3 Fatty Acids for Prevention of Post-Operative Atrial Fibrillation (OPERA) Trial. (2018) (5)
Epistatic Interactions in Genetic Regulation of t-PA and PAI-1 Levels in a Ghanaian Population (2011) (5)
GSK2256294 Decreases sEH (Soluble Epoxide Hydrolase) Activity in Plasma, Muscle, and Adipose and Reduces F2-Isoprostanes but Does Not Alter Insulin Sensitivity in Humans (2021) (4)
Genetic Effects on the Correlation Structure of CVD Risk Factors: Exome-Wide Data From a Ghanaian Population. (2017) (4)
Changes in B-Type Natriuretic Peptide and BMI Following Roux-en-Y Gastric Bypass Surgery (2014) (4)
Bradykinin B(2) receptor does not contribute to blood pressure lowering during AT(1) receptor blockade. (2007) (3)
Examining EXAMINE for an Interaction With Angiotensin-Converting Enzyme Inhibition. (2016) (3)
Retrospective cohort study to characterise the blood pressure response to spironolactone in patients with apparent therapy-resistant hypertension using electronic medical record data (2020) (3)
Salt in the wound. (2009) (3)
Comparative effects of weight loss and incretin‐based therapies on vascular endothelial function, fibrinolysis and inflammation in individuals with obesity and prediabetes: A randomized controlled trial (2022) (3)
Abstract P180: Quantification of Substance P in Human Blood by Mass Spectroscopy (2016) (2)
Association of Apparent Treatment-Resistant Hypertension With Differential Risk of End-Stage Kidney Disease Across Racial Groups in the Million Veteran Program (2021) (2)
Endogenous Bradykinin and BK1-5 during ACE Inhibitor-Associated Angioedema (2018) (2)
Plasminogen activator inhibitor type 1 in diabetes and hypertension (1997) (2)
DPP4 (Dipeptidyl Peptidase-4) Inhibition Increases Catecholamines Without Increasing Blood Pressure During Sustained ACE (Angiotensin-Converting Enzyme) Inhibitor Treatment (2022) (2)
Increased Serum BNP Concentrations Are Associated With Pulmonary Vascular Dysfunction In Patients With Acute Lung Injury (2010) (2)
Statins to Reduce Acute Kidney Injury After Cardiac Surgery--Reply. (2016) (2)
Abstract 4404: Variation in the 4q25 Chromosomal Locus Predicts New-Onset Atrial Fibrillation after Cardiac Surgery (2008) (2)
Dipeptidyl Peptidase IV in Angiotensin-Converting Enzyme Inhibitor-Associated Angioedema. Commentary (2008) (1)
OR05-6 The Effect of the GLP1R Variant rs6923761 on Post-Prandial Glucose Levels during Treatment with Sitagliptin (2019) (1)
The molecular mechanisms of calcium dependent tissue-type plasminogen activator release (2003) (1)
Cancer Therapy-Related Hypertension: A Scientific Statement From the American Heart Association. (2023) (1)
Beta‐2 Adrenergic Receptor (BAR2) Poly‐morphism is Not Associated with Essential Hypertension (HT) in African‐Americans (AA) or Caucasian‐Americans (CA) (1999) (1)
Co‐Administration of Glyburide and Minoxidil, Drugs with Opposing Effects on Potassium Channels (1996) (1)
MON-474 Dipeptidyl Peptidase-4 (DPP4) Inhibition Decreases Visceral Fat and Improves Glucose Metabolism in Overweight Women with Polycystic Ovarian Syndrome (2019) (1)
Baseline Data Incorrect. (2016) (1)
Abstract P147: Differences in the Treatment of Resistant Hypertension in African Americans and European Americans in a Clinical Setting (2017) (1)
Treatment of Primary Aldosteronism Increases Plasma Epoxyeicosatrienoic Acids (2021) (1)
Abstract 16499: Preamyloid Oligomers are Present in Human Atrium and Are Associated With Post-Operative Atrial Fibrillation (2011) (1)
Dipeptidyl peptidase IV gene associates with angiotensin-converting enzyme inhibitor-associated angioedema and with serum dipeptidyl peptidase IV in black americans (2008) (0)
Faculty Opinions recommendation of Epoxyeicosanoids stimulate multiorgan metastasis and tumor dormancy escape in mice. (2012) (0)
The soluble epoxide hydrolase inhibitor GSK2256294 decreases the proportion of adipose pro-inflammatory T cells. (2021) (0)
Response to Letter Regarding Article, “Plasminogen Activator Inhibitor-1 as a Predictor of Postoperative Atrial Fibrillation After Cardiopulmonary Bypass” (2008) (0)
Abstract 270: Successful Development and Implementation of an Algorithm to Identify Resistant Hypertension in the Electronic Medical Record (2014) (0)
Faculty Opinions recommendation of Saxagliptin and cardiovascular outcomes in patients with type 2 diabetes mellitus. (2013) (0)
ACE I/D Genotype Determines in Vivo Bradykinin Metabolism in Humans (2000) (0)
Angiotensin-converting enzyme activity is decreased in dipeptidyl peptidase IV-deficient male rats (2008) (0)
Abstract 080: Characterization of Blood Pressure Response to Spironolactone in Patients With Resistant Hypertension using Electronic Medical Records (2018) (0)
Abstract 256: Loss-of-function Gln287 Variant in EPHX2 is Associated With Increased Insulin Sensitivity (2013) (0)
Abstract 32: Mitochondrial DNA Copy Number and Oxidative Stress in Patients with Chronic Kidney Disease (2013) (0)
The Contribution of Arachidonic Acid Metabolites EETs to Inflammation in Obesity (2021) (0)
Abstract 3350: Plasminogen Activator Inhibitor-1 as a Predictor of Postoperative Atrial Fibrillation Following Cardiopulmonary Bypass (2006) (0)
Abstract 063: Phosphodiesterase 5 Inhibition Improves Insulin Sensitivity and Disposition Index in Prediabetes without Altering Glucose-Stimulated Insulin Secretion (2014) (0)
Abstract P026: Relationship Between Antihypertensive Adherence and Emergency Department Blood Pressure (2015) (0)
MOST CIRCULATING BNP IS NOT ACTIVE BNP1-32, WHICH DECREASES DURING CHRONIC THERAPY WITH SACUBITRIL/VALSARTAN (2021) (0)
Activator Release in Women But Not in Men Angiotensin-Converting Enzyme Inhibition Increases Basal Vascular Tissue Plasminogen (2005) (0)
Abstract 230: Angiotensin-Converting Enzyme Inhibition Increases ADMA Concentration in Patients on Hemodialysis (2014) (0)
Correction: Epistatic Interactions in Genetic Regulation of t-PA and PAI-1 Levels in a Ghanaian Population (2011) (0)
Natriuretic Peptide , Aldosterone , and Fluid Management in Acute Respiratory Distress Syndrome (2016) (0)
Abstract 355: Mineralocorticoid Receptor Activation Alters Epoxyeicosatrienoic Acid Production In Vivo (2013) (0)
Proneuropeptide Y and neuropeptide Y metabolites in healthy volunteers and patients with a pheochromocytoma or paraganglioma. (2022) (0)
Abstract 613: Interactive Effect of Ace Inhibition and DPP4 Inhibition on Substance P-Stimulated T-PA Release (2012) (0)
Abstract 107: Bradykinin B 2 Receptor Blockade Prevents Excessive Blood Pressure Reduction During Hemodialysis (2019) (0)
Abstract P2024: Treatment of Primary Hyperaldosteronism Increases Plasma Epoxyeicosatrienoic Acids (2019) (0)
Seasonal presentation of angiotensin-converting enzyme inhibitor-associated angioedema (2011) (0)
Abstract P050: Loss-of-function Cyp4a11 Variants Are Associated With Apparent Treatment Resistant Hypertension Identified In Electronic Medical Records; In The VA Million Veteran’s Program And Vanderbilt’s BioVU (2022) (0)
Increased prevalence of transplant recipients among cases of angiotensin-converting enzyme inhibitor-associated angioedema (2008) (0)
2016 Reviewer Acknowledgment (2017) (0)
Abstract 360: Genetic Variants Associated With ACE Inhibitor-Associated Angioedema (2012) (0)
Abstract 531: Regulation of Plasma 20-HETE and Soluble Epoxide Hydrolase by Salt Balance in Normotensive Subjects (2014) (0)
Update in Conflict of Interest Disclosure and Errors in the Supplement and Figure. (2016) (0)
Abstract 079: Dipeptidyl Peptidase IV (DPP4) Inhibition Enhances the Vasoconstrictor Response to Neuropeptide Y During Angiotensin-converting Enzyme Inhibition (2017) (0)
ACE I/D Genotype Determines in Vivo Bradykinin Metabolism in Humans (2000) (0)
Abstract P635: Effect of Patient Characteristics and DPP4 genotype on Dipeptidyl Peptidase IV Activity and Inhibition by Sitagliptin (2016) (0)
Introduction. P450 metabolites of arachidonic acid--from biochemistry to therapy. (2013) (0)
Response by Hubers and Brown to Letter Regarding Article, "Combined Angiotensin Receptor Antagonism and Neprilysin Inhibition". (2016) (0)
The Cardiovascular Effects of Peptidase Inhibition (2018) (0)
Response to Interleukin-6 Antagonists for the Management of Hypertension (2007) (0)
March 15 , 2016 by blocking vascular and adrenal (2016) (0)
RF32 | PSUN60 Bioactive Natriuretic Peptides Measured By Mass Spectrometry and Associations With BMI, Race, and Metabolic Markers (2022) (0)
Iconographies supplémentaires de l'article : Increased sensitivity to bradykinin among African Americans (2011) (0)
Abstract 305: Association Between CYP4A11 Variant and Response to Spironolactone, but Not ENac Inhibitor Amiloride (2012) (0)
1007-182 Aldosterone and plasma renin activity influence plasma plasminogen activato inhibitor-1 levels in overweight subjects (2004) (0)
Abstract P253: Angiotensin Converting Enzyme Inhibition vs. Angiotensin II Receptor Blockade in Marfan Mouse: Role of Bradykinin (2015) (0)
Abstract P307: Effect of Bradykinin Receptor Antagonism on ACE Associated Angioedema (2016) (0)
Comparative Effects of Weight Loss and Incretin-Based Therapies on Endothelial Vasodilatory and Fibrinolytic Function (2022) (0)
Coordinated responses of plasma 20-HETE and soluble epoxide hydrolase to salt in normal subjects: alterations in salt-sensitive normotension (2014) (0)
ActionRefreshing a Slow Hormone by Swift (2015) (0)
Genetic variants in DPP4 and XNPEP2 associate with ACE inhibitor-associated angioedema (2009) (0)
418 Activation of the Glucagon-Like Peptide-1 Pathway in Obese Pre-Diabetic Individuals Improves Endothelial Function Independently of Weight Loss (2022) (0)
During Angiotensin-Converting Enzyme Inhibition Bradykinin Type 2 Receptor BE 1 Genotype Influences Bradykinin-Dependent (2008) (0)
The role of endothelial-derived hyperpolarizing factor in tissue-type plasminogen activator release (2003) (0)
Active B-Type Natriuretic Peptide Measured by Mass Spectrometry and Response to Sacubitril/Valsartan (2021) (0)
Response to Letter to the Editor: “Hypertension and Type 2 Diabetes Are Associated With Decreased Inhibition of Dipeptidyl Peptidase-4 by Sitagliptin” (2020) (0)
THE PREPARATION AND CHARACTERIZATION OF NOVEL PEPTIDE ANTAGONISTS TO THROMBIN, FACTOR VIIa AND ACTIVATION OF PROTEASE ACTIVATED RECEPTOR1 § (2004) (0)
Loss of normal dietary sodium blood pressure response to angiotensin ii infusion in human essential hypertension (2004) (0)
Obesity and Overweight: Probing Causes, Consequences, and Novel Therapeutic Approaches Through the American Heart Association's Strategically Focused Research Network. (2023) (0)
Faculty Opinions recommendation of The absence of intrarenal ACE protects against hypertension. (2013) (0)
Connecting Generations of Scientists in the Council on Hypertension Through Harriet Dustan. (2021) (0)
Abstract 227: A Liquid Chromatography-Mass Spectrometry Assay for the Semi-quantitative Screening of 34 Cardiovascular Medications in Human Serum (2013) (0)
SAT-051 Higher Urinary Cortisol Levels Associated with Increased Cardiovascular Risk (2019) (0)
Comparison of Pharmacy Refill Data With Chemical Adherence Testing in Assessing Medication Nonadherence in a Safety Net Hospital Setting (2022) (0)
43 THYROID FUNCTION AFFECTS BLOOD PRESSURE HOMEOSTASIS IN EUTHYROID HUMANS. (2004) (0)
Abstract P133: Prevalence Of Medication Non-adherence Via Therapeutic Drug Monitoring In Patients With Uncontrolled Hypertension Treated At A Safety Net Hospital (2021) (0)
MO045MITOCHONDRIAL DYSFUNCTION AND MUSCLE ENERGETICS IN CKD PATIENTS (2020) (0)
β-2 adrenergic receptor diplotype defines a subset of salt-sensitive hypertension. Commentary (2006) (0)
Abstract 15870: Weight Gain Vs Stable Obesity in Middle Age is Associated With Higher Burden of Cardiometabolic Disease and Overall Comorbidity (2018) (0)
Faculty Opinions recommendation of Rosuvastatin and cardiovascular events in patients undergoing hemodialysis. (2009) (0)
Abstract 18516: Common Atrial Fibrillation Susceptibility Alleles Enhance Clinical Risk Prediction Model for Postoperative Atrial fibrillation (2012) (0)
Comparative effects of immediate‐release and extended‐release aspirin on basal and bradykinin‐stimulated excretion of thromboxane and prostacyclin metabolites (2016) (0)
Letter by Brown and Pretorius regarding article, "effect of sulfaphenazole on tissue plasminogen activator release in normotensive subjects and hypertensive patients". (2009) (0)
Erratum to “Characterization of the CYP4A11 gene, a second CYP4A gene in humans” [Arch. Biochem. Biophys. 409 (2003) 221–227] (2003) (0)
Abstract 95: Glucagon Like Peptide-1 (GLP-1) Does Not Cause Vasodilation Even When Dipeptidyl Peptidase 4 (DPP4) is Inhibited (2013) (0)
Contribution of Coagulation Pathways and Fibrinolysis in Generation of Kinins. (2006) (0)
Faculty Opinions recommendation of Salt-dependent inhibition of epithelial Na+ channel-mediated sodium reabsorption in the aldosterone-sensitive distal nephron by bradykinin. (2012) (0)
Abstract P328: Effect of Sitagliptin on the Hemodynamic and Metabolic Response to a Mixed Meal in Individuals With Type 2 Diabetes and Hypertension (2018) (0)
Differences in the frequency of Arg492⇒Cys polymorphism of the human α1A‐adrenergic receptor (α1A‐AR) in African‐Americans (AA) and Caucasians (CA) (1999) (0)
Interethnic Differences in Beta‐2 Adrenoceptor (BAR2) Polymorphisms in African‐American (AA), Caucasian (CA), and Chinese (CHN) Populations (1999) (0)
Abstract P136: Comparison of Pharmacy Refill Data With Therapeutic Drug Monitoring (TDM) in Assessing Non-Adherence to Cardiovascular Drugs in Patients With Uncontrolled Hypertension (2019) (0)
Mineralocorticoid Receptor Activation and Atrial Fibrosis. (2019) (0)
Prostaglandins and Other Lipid Mediators eview poxyeicosatrienoic acids and glucose homeostasis in mice and men ames (2016) (0)
Mineralocorticoid Receptor Blockers and Aldosterone Synthase Inhibitors (2018) (0)
Bradykinin B2 receptor BE1 genotype influences bradykinin-dependent vasodilation in humans during ACE inhibition (2007) (0)
Abstract 094: Gain-of-function EPHX2 Variant rs41507953 Is Associated With Acute Kidney Injury Following Cardiac Surgery (2015) (0)
SUN-544 Immunologic Effects of GLP-1 Activation in Obese Adipose Tissue (2020) (0)
Misspelled Author Name. (2016) (0)
LBSUN306 Effects Of Glp-1 Receptor Agonism, Dpp4 Inhibition, And Hypocaloric Diet On Metabolic Parameters In Obese Pre-diabetic Individuals: A Randomized-controlled Trial (2022) (0)

This paper list is powered by the following services:

What Schools Are Affiliated With Nancy J. Brown?

Nancy J. Brown is affiliated with the following schools:

Nancy J. Brown's Academic­Influence.com Rankings

Nancy J. Brown's Degrees

Why Is Nancy J. Brown Influential?

Nancy J. Brown's Published Works

Published Works

What Schools Are Affiliated With Nancy J. Brown?

Nancy J. Brown's AcademicInfluence.com Rankings